Signals Inbox·September 2, 2026·Biopharma

Can an arthritis drug really regrow hair?

Yes. Rinvoq can regrow striking amounts of hair in severe alopecia areata, with two large Phase 3 trials now showing the effect is real, repeatable and much narrower than the “arthritis pill cures baldness” headline.

Q1Why is the arthritis drug Rinvoq suddenly being talked about for hair loss?

Rinvoq is suddenly part of the hair-loss conversation because two large Phase 3 trials found that the arthritis drug can regrow a remarkable amount of hair in people with severe alopecia areata.

Rinvoq, whose generic name is upadacitinib, has been used for years against immune-mediated diseases including rheumatoid arthritis, psoriatic arthritis, Crohn's disease and atopic dermatitis. AbbVie then tested the same oral drug against alopecia areata, an autoimmune disease in which immune activity around the hair follicle drives hair loss.

The evidence has become much harder to dismiss lately. The full UP-AA1 and UP-AA2 trials were published in JAMA Dermatology only a few weeks ago. Together, they randomized 1,399 adults and adolescents with severe alopecia areata to Rinvoq 15 mg, Rinvoq 30 mg or placebo.

The arthritis connection sounds stranger than the biology really is. Rinvoq blocks JAK signaling involved in inflammatory communication inside the immune system. Similar signaling pathways are involved in alopecia areata, where follicles can remain alive even after years without producing visible hair. Suppress the immune attack enough, and some of those follicles can start growing again.

That leaves us with a much narrower claim than “an arthritis pill cures baldness,” but a much more credible one: Rinvoq can currently produce major hair regrowth in severe autoimmune alopecia.

Q2Did Rinvoq actually regrow hair in the Phase 3 trials?

The Phase 3 Rinvoq results are strong: roughly half of patients with severe alopecia areata recovered at least 80% scalp coverage within six months, while almost nobody on placebo did.

UP-AA1 and UP-AA2 were separate randomized, double-blind studies, which gives us a useful built-in replication test. In UP-AA1, 45.2% of patients taking 15 mg reached a SALT score of 20 or below after 24 weeks. UP-AA2 came out at 44.6%.

The higher dose was just as consistent. Rinvoq 30 mg produced response rates of 55.0% and 54.3% in the two trials.

Meanwhile, placebo produced 1.5% and 3.4%.

The two trials land within about one percentage point of each other for both Rinvoq doses. That level of replication is unusually reassuring. Pooling the raw numbers, only 7 of 280 placebo patients reached the main endpoint, compared with 251 of 559 patients assigned to 15 mg and 306 of 560 assigned to 30 mg.

Rinvoq also produced much deeper responses. Around 35% to 36% of patients taking 15 mg and 46% to 47% taking 30 mg ended up with at least 90% scalp coverage. Complete scalp coverage occurred in around 13% to 14% and 20% to 23%, respectively.

Rinvoq scalp-hair outcomes after 24 weeks

Q3Does “80% hair regrowth” mean Rinvoq patients got 80% of their lost hair back?

No. The popular “80% hair regrowth” description makes the Rinvoq result sound more universal than it actually was.

The trials used the Severity of Alopecia Tool, or SALT. A SALT score of 100 means the scalp has essentially no hair. SALT 20 means 20% or less of the scalp remains without hair.

The main Rinvoq endpoint was therefore reaching SALT 20 or below, which translates into at least 80% scalp coverage. It does not mean every successful patient regrew 80% of whatever hair they personally had lost.

Someone who entered at SALT 100 and reached SALT 20 recovered roughly 80 percentage points of scalp coverage. Someone beginning at SALT 60 and ending at SALT 20 also counted as a responder, despite recovering considerably less.

So when we see claims that Rinvoq “regrew 80% of hair,” we should read them carefully. About 45% of patients on 15 mg and 55% on 30 mg reached at least 80% scalp coverage. The result is still impressive once described correctly.

Q4Were Rinvoq patients likely to regrow their hair naturally anyway?

Spontaneous recovery cannot realistically explain the Rinvoq results because these were unusually severe and long-running alopecia cases.

The average patient entered UP-AA1 or UP-AA2 with a SALT score of 83.9, meaning roughly 84% of the scalp was already missing hair.

About half began with at least 95% scalp hair loss. Roughly one-third had alopecia totalis or alopecia universalis, the extreme forms associated with complete scalp loss or loss across much of the body.

The disease was hardly new either. Participants had typically been living with alopecia for years, and the trials excluded people showing recent spontaneous scalp regrowth before enrollment.

Then we can look at what actually happened without active treatment. Across 280 placebo patients, only seven reached the main hair-coverage endpoint after 24 weeks.

That placebo rate gives us a useful baseline. In this kind of severe, persistent alopecia areata, dramatic spontaneous recovery over the next six months appears uncommon. Rinvoq moved the response rate from low single digits to roughly half of treated patients.

Q5Did anyone taking Rinvoq actually get all their scalp hair back?

Yes. Complete scalp hair regrowth happened often enough with Rinvoq that we cannot treat it as an anecdotal outlier.

JAMA Dermatology reported that 14.1% of patients on Rinvoq 15 mg in UP-AA1 and 13.1% in UP-AA2 reached SALT 0 after 24 weeks. SALT 0 means no measurable scalp hair loss.

The 30 mg dose pushed those figures to 20.3% and 22.5%. Placebo produced zero complete responders in one trial and one patient in the other.

So around one in five people receiving the higher Rinvoq dose went from severe alopecia areata to complete scalp coverage within six months.

We also see a much larger group stopping just short of that mark. Around 46% of patients on 30 mg reached at least 90% scalp coverage.

Those numbers make the effect visually meaningful. We are talking about people recovering enough hair to move from severe baldness toward a nearly full or completely full scalp, not merely producing small patches of new growth.

Q6How fast does Rinvoq regrow hair, and does it keep improving after six months?

Rinvoq can start separating from placebo within about eight weeks, but the hair-regrowth curve keeps moving for many months after that.

In both Phase 3 trials, Rinvoq patients were already reaching the main SALT endpoint at significantly higher rates than placebo by week eight. Deeper outcomes such as near-complete or complete coverage also began appearing around weeks eight to twelve, depending on the dose and trial.

Stopping at six months would miss a large part of the response.

AbbVie's 52-week UP-AA data show that 59.3% and 55.0% of patients taking 15 mg eventually reached at least 80% scalp coverage in the two studies. With 30 mg, the figures reached 63.8% and 63.3%.

Complete coverage kept improving even faster. By one year, around 27% to 29% of patients taking 15 mg had reached SALT 0. With 30 mg, approximately 36% to 37% had.

We need one caveat here: placebo treatment ended after week 24, so the 52-week figures no longer come from a continuing placebo comparison. Still, both trials show almost the same trajectory.

For patients considering Rinvoq today, six months looks more like an important checkpoint than a final ceiling. Some people respond early, while others continue filling in for much longer.

Q7Can Rinvoq regrow eyebrows and eyelashes too?

Rinvoq can regrow eyebrows and eyelashes as well as scalp hair, and the effect was again far larger than placebo.

Among patients who began the trials with substantial eyebrow loss, around 41% of those taking 15 mg reached full or nearly full eyebrow coverage with a major improvement after 24 weeks.

Rinvoq 30 mg pushed the figure to roughly 59% to 62%. Placebo produced only about 1% to 3%.

The eyelash results followed almost the same pattern. Around 43% of patients on 15 mg reached full or nearly full eyelashes with major improvement. The 30 mg groups reached roughly 59% and 61%, versus around 4% to 6% on placebo.

The same drug is changing three separate manifestations of the disease at once: scalp hair, eyebrows and eyelashes.

That fits well with what we know about alopecia areata. Rinvoq is acting on the systemic autoimmune process affecting hair follicles across the body, which explains why regrowth can appear in several places together.

Q8Can Rinvoq regrow ordinary male-pattern or female-pattern baldness?

Rinvoq currently has no convincing clinical evidence showing that it can reverse ordinary male-pattern or female-pattern hair loss.

This is probably the biggest limitation hidden by the phrase “arthritis drug regrows hair.”

UP-AA1 and UP-AA2 studied alopecia areata, where the immune system attacks hair follicles. Common androgenetic alopecia works differently. Genetically susceptible follicles gradually miniaturize under androgen signaling, particularly dihydrotestosterone.

Rinvoq targets inflammatory JAK pathways. We have no comparable Phase 3 evidence showing that systemic JAK inhibition reverses that common form of baldness.

The patient profile is wildly different. The average person in the Rinvoq trials had lost roughly 84% of their scalp hair from severe autoimmune disease. A man with a slowly receding hairline or a woman developing gradual crown thinning is dealing with another biological problem.

So a person searching for a stronger alternative to finasteride or minoxidil should not read the Rinvoq results as evidence that a new general baldness drug has arrived.

Q9Is Rinvoq better than Olumiant, Litfulo and Leqselvi for alopecia areata?

Rinvoq currently has the strongest headline response rates among the major oral JAK treatments studied for severe alopecia areata, although no head-to-head trial has proved that it is actually superior.

The easiest comparison is the proportion of patients reaching SALT 20 or below, meaning at least 80% scalp coverage.

Pfizer's Litfulo reached 23% at week 24 in the regimen approved by the FDA, versus 1.6% with placebo.

Sun Pharma's Leqselvi reached 29% and 32% in its two Phase 3 trials at week 24, with placebo around 1%.

Eli Lilly's Olumiant reached 35% and 32% with its 4 mg dose, although its main endpoint was measured later at week 36.

Rinvoq came out at roughly 45% with 15 mg and 54% to 55% with 30 mg at week 24.

Those differences are large enough to get our attention. They are still cross-trial comparisons, though. The trials enrolled different patients and used different designs, and Olumiant had twelve extra weeks before its primary measurement.

For now, Rinvoq sits at the high end of the efficacy range we have seen from oral JAK inhibitors. It has not, however, been proven better than every alternative.

Oral alopecia treatments by pivotal SALT ≤20 result

Q10Is Rinvoq 30 mg worth taking instead of 15 mg for alopecia areata?

Rinvoq 30 mg clearly regrows more hair than 15 mg, but the extra efficacy comes with a visible increase in side effects.

The dose-response pattern appears almost everywhere in UP-AA1 and UP-AA2. The higher dose produced about ten percentage points more patients reaching the main scalp endpoint after six months. It also generated substantially more complete regrowth and stronger eyebrow and eyelash responses.

Side effects moved upward too.

Across the pooled safety data, 62.7% of patients on 15 mg reported at least one treatment-emergent adverse event, compared with 67.1% on 30 mg. Serious adverse events rose from 1.6% to 2.3%.

Acne gives us the clearest everyday example. It affected 11.7% of patients on 15 mg and 16.3% on 30 mg, versus 3.6% on placebo. Neutropenia also became more frequent as the dose increased.

There is no universal answer to whether those extra percentage points of hair regrowth justify the higher dose. The trade-off changes with disease severity, medical history, age and how someone values a faster or deeper response.

Rinvoq safety events during the first 24 weeks

Q11How risky is Rinvoq when someone is taking it for hair loss?

Rinvoq has a much heavier safety profile than ordinary hair-loss treatments because the drug changes immune signaling throughout the body.

Current US Rinvoq prescribing information carries major warnings covering serious infections, malignancies, cardiovascular events, thrombosis and increased mortality in certain higher-risk populations treated with JAK inhibitors.

The alopecia trials themselves looked considerably calmer. Researchers recorded no deaths and no adjudicated major cardiovascular events during the placebo-controlled period. One venous thromboembolism occurred in the 15 mg group, in a patient who had several existing risk factors. One breast cancer case was also reported in that dose group in a patient with pre-existing breast nodules.

Those data are useful but cannot settle the long-term safety question. A trial containing roughly 1,400 patients and following the placebo groups for six months can pick up common problems quite well. Rare events that emerge over years need much larger exposure.

The trade-off gets especially tricky in alopecia areata because many patients are young and otherwise healthy. Someone with devastating alopecia universalis may reasonably view systemic treatment very differently from somebody with a small bald patch.

Rinvoq's short-term alopecia safety data are fairly reassuring. The broader JAK safety warnings remain real.

Q12Will the hair stay if someone stops taking Rinvoq?

We do not yet have strong Rinvoq withdrawal data showing that the regrown hair stays after treatment stops, and experience with another JAK inhibitor suggests that long-term relapse will be common.

The best experiment we currently have comes from baricitinib, sold as Olumiant.

In the BRAVE-AA1 trial, patients who had successfully regrown hair after one year were randomly assigned either to continue baricitinib or switch to placebo. Hair initially stayed surprisingly stable. Four weeks after stopping, essentially nobody had lost the treatment benefit, and only around 10% to 11% had lost it after eight weeks.

Then the curves diverged sharply.

After 100 weeks of withdrawal follow-up, 80% of patients who had stopped baricitinib had lost their treatment benefit. Among people who kept taking the drug, only 7% did.

Restarting baricitinib restored the response in many of the patients who relapsed, although recovery was not immediate or universal.

We cannot simply copy that exact relapse rate onto Rinvoq. But both drugs suppress JAK-dependent immune pathways in the same chronic autoimmune disease. Until Rinvoq-specific withdrawal studies show otherwise, expecting permanent hair retention after stopping would be optimistic.

Q13Does Rinvoq actually cure alopecia areata?

Rinvoq can make severe alopecia areata disappear visually, but currently we have no evidence that it permanently removes the disease itself.

That difference becomes easy to miss when someone goes from almost no scalp hair to complete coverage.

With Rinvoq, some patients reach SALT 0. Their scalp can look fully restored. Eyebrows and eyelashes can return too.

Yet JAK inhibition works by keeping inflammatory signaling under control. Existing evidence from the same drug class shows that the underlying autoimmune tendency can reassert itself once treatment disappears.

As seen above, the baricitinib withdrawal experiment is particularly hard to ignore: most long-term responders eventually lost the benefit after stopping treatment.

We would need durable Rinvoq remission after withdrawal to start talking seriously about a cure. Today, the evidence fits long-term disease control much better.

For someone who regrows a full head of hair, that may still feel transformative. Medically, though, the difference between complete regrowth and permanent remission remains important.

Q14Can people actually get Rinvoq for alopecia areata today?

Rinvoq is already approved for severe alopecia areata in the European Union, while US approval for hair loss is still pending.

The European Commission approved the 15 mg and 30 mg doses for adults and adolescents aged 12 and older with severe alopecia areata after reviewing the UP-AA program.

The US situation is currently different. AbbVie submitted Rinvoq to the FDA for the same alopecia indication earlier this year, but the company's current US Rinvoq website still lists nine approved conditions and alopecia areata is absent from that list.

American patients do already have several FDA-approved systemic options. Olumiant is approved for adults with severe alopecia areata, Litfulo for adults and adolescents aged 12 and older, and Leqselvi for adults.

So people reading about the new Rinvoq results today are seeing the evidence slightly ahead of the US label.

The practical situation can therefore vary a lot by country. Rinvoq has already crossed the regulatory line for alopecia in Europe, while Americans are currently waiting for the FDA decision on this specific use.

Q15So can an arthritis drug really regrow hair?

Yes. Rinvoq really can regrow large amounts of hair, and the evidence is now strong enough that the basic claim is no longer surprising.

We have two large randomized Phase 3 trials producing almost identical results, a freshly published JAMA Dermatology paper, continued improvement through one year and regulatory approval in Europe.

As seen above, roughly 45% of patients on Rinvoq 15 mg and 55% on 30 mg reached substantial scalp coverage within six months, compared with only a few percent on placebo. Some patients recovered every measurable bit of scalp hair, while eyebrows and eyelashes also returned in many cases.

The catch is much narrower than the headline makes it sound. Rinvoq has shown this effect in severe alopecia areata, where an autoimmune attack is suppressing hair follicles. We currently have no comparable evidence that it reverses ordinary male-pattern or female-pattern baldness.

And the treatment comes with a serious trade-off. Rinvoq is systemic immune therapy, carries JAK-inhibitor safety warnings and will probably need to be continued in many patients to preserve the regrowth.

So yes: the arthritis-drug story is true, and the hair regrowth is genuinely impressive. Rinvoq is becoming one of the strongest treatments we have seen for severe alopecia areata. Calling it a general or permanent cure for baldness goes far beyond what the evidence shows today.